British journal of cancer
-
British journal of cancer · Feb 2019
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide. ⋯ In HGSOC and BC, olaparib 300 mg bid and cyclophosphamide 50 mg on days 1-5 weekly were tolerable and active, particularly in gBRCAm, and is worthy of further investigation.